What Romal Treats: Main Uses and Benefits

Romal is commonly used to help with symptoms related to physical discomfort and systemic imbalance, which may interfere with daily functioning.

Romal is applied across domains where additional symptomatic support is needed, addressing conditions involving inflammatory or irritative processes, such as chronic joint diseases like rheumatoid arthritis and osteoarthritis, acute conditions such as sprains, strains, and tendinitis, and episodic pain, including primary dysmenorrhea (menstrual cramps). The medication is generally applied in scenarios where additional management of discomfort is required, such as during the post-traumatic or postoperative phase.

Quick Fact: Relief for Pain, Inflammation, and Fever

This medication helps address symptom clusters that may become intense or disruptive, and is commonly used to help with symptoms related to physical discomfort, stiffness, and systemic imbalance. This action contributes to improved comfort during periods of heightened symptoms.

Regulatory References

1. Health Canada Product Monograph

Official Eligibility and Restriction Profile

Romal (Ketoprofen) is approved primarily for use in adults (typically 18 years and older). Regulatory agencies define specific populations who are prohibited from use (Contraindicated) or who require close monitoring (Restricted Use).

Classification	Population or Status	Constraint
Contraindicated	Patients with known hypersensitivity to Ketoprofen, Aspirin, or other NSAIDs (risk of severe allergic reaction).	Absolutely prohibited.
Contraindicated	Treatment of perioperative pain following coronary artery bypass graft (CABG) surgery.	Absolutely prohibited.
Contraindicated	Patients with active peptic ulceration or active inflammatory gastrointestinal disease.	Absolutely prohibited.
Contraindicated	Use during the last trimester of pregnancy (from 30 weeks gestation onward).	Absolutely prohibited.
Use Not Established	Pediatric population (children and adolescents).	Safety and efficacy have not been formally established.
Restricted Use	Older adults (65+ years) and patients with impaired renal or hepatic function.	Requires close monitoring and conditional use.
Not Recommended	Nursing mothers (lactation).	Use is generally avoided due to lack of established data.

The overall profile restricts use based on age, reproductive status, and the presence of severe pre-existing comorbidities (e.g., active GI disease or organ impairment) as defined by official regulatory documentation.

Interaction scope

Category	Official Regulatory Statements
Medicinal product categories with documented interactions	Anticoagulants, Antiplatelet agents, Oral Corticosteroids, Selective Serotonin Reuptake Inhibitors (SSRIs), Diuretics, ACE Inhibitors, Angiotensin II Receptor Blockers (ARBs), Lithium, Methotrexate.
Specific interacting medicines (if explicitly listed)	Warfarin, Aspirin, Probenecid.
Mechanistic basis of interactions (only if stated in label)	Pharmacodynamic enhancement of bleeding risk; Pharmacodynamic reduction of antihypertensive or diuretic effect; Pharmacokinetic reduction of clearance for co-administered agents (e.g., Lithium, Methotrexate); Ketoprofen metabolism involves glucuronide conjugation, and it does not induce drug-metabolizing enzymes.
Timing-based interaction rules (if applicable)	No specific mandatory time-separation rule (e.g., "must be separated by X hours") is officially documented in the primary regulatory warnings.
Population-specific interaction notes (if applicable)	Elderly patients are at greater risk for serious gastrointestinal events; Renally Impaired Patients face greater risk of renal failure with certain co-administered agents and risk of glucuronide metabolite accumulation.
Interaction-related restrictions	Contraindicated in the setting of peri-operative pain for Coronary Artery Bypass Graft (CABG) surgery; Contraindicated in patients with known hypersensitivity reactions to Aspirin or other NSAIDs.

Interaction classifications (high-level)

Classification	Official Regulatory Statements
Interaction severity classification (as defined in official documents)	Contraindicated combinations (e.g., CABG setting); Clinically significant interactions requiring monitoring and caution (e.g., with Lithium, Anticoagulants).
Regulatory basis (EMA / FDA / etc.)	FDA Prescribing Information / NIH DailyMed.
Interaction-context constraints (as defined in official documents)	Increased risk when co-administered with Alcohol (gastrointestinal bleeding); High-fat meals cause a delay in reaching peak plasma concentration for extended-release oral forms.

Resulting interaction structure

The regulatory documents define the interaction structure of Romal primarily through numerous pharmacodynamic interactions that heighten the risk of bleeding or compromise renal function with common cardiovascular and anti-inflammatory drug classes. The profile is further constrained by pharmacokinetic interactions that specifically reduce the clearance and increase the plasma concentration of co-administered agents like Lithium and Methotrexate. These documented findings impose explicit restrictions, such as the contraindication for use in the peri-operative CABG setting.

Non-Selective Inhibition of Prostaglandin Synthesis

The mechanism of Romal (Ketoprofen) involves the non-selective competitive reversible inhibition of the Cyclooxygenase (COX) enzymes, targeting both the COX-1 and COX-2 isoforms. This blockade prevents the formation of key lipid mediators, such as prostaglandins ( PGE2), by interfering with the conversion of arachidonic acid. This action directly influences the molecular pathway that generates acute physiological responses.

Modulation of Nociceptor and Vascular Signaling

The resulting reduction of PGE2 synthesis leads to the dampening of peripheral nociceptor sensitization and modulates the chemical signals that mediate increased vascular permeability and localized fluid accumulation. This mechanistic effect primarily targets the amplification of signaling, contributing to the modulation of chemical signaling within peripheral response pathways.

Central Thermoregulation Reset

The mechanism extends to the Central Nervous System (CNS), where the molecule inhibits PGE2 synthesis within the hypothalamus. This targeted central action normalizes the body's thermoregulatory set point, which had been inappropriately elevated, resulting in the normalization of the elevated core body temperature set point.

How to Use Romal: Official Administration Guidelines

The usage of Romal (Ketoprofen) is defined by administration instructions to ensure proper systemic or localized delivery. The medication is available in oral forms (immediate-release and extended-release capsules/tablets) and topical forms (gel).

Oral administration follows distinct schedules based on the formulation. Immediate-release oral forms are typically administered in divided doses throughout the day—for example, 75 mg three times daily or 50 mg four times daily for conditions like arthritis. Acute pain management utilizes doses of 25 mg to 50 mg every six to eight hours as needed. The total daily dose for the immediate-release form generally must not exceed 300 mg. The extended-release form is administered once daily at a dose of 200 mg.

Administration Conditions and Constraints

Constraint	Instruction
Timing & Food	Oral forms may be taken with food, milk, or an antacid.
ER Handling	Extended-release forms must be swallowed whole; they must not be crushed or chewed.
Topical Use	Apply 5 to 10 cm of gel (2 to 4 g) to the affected area two to four times daily.

Population-Specific Use

In older or debilitated adults, a lower initial dose is required, with careful monitoring. For patients with severe renal or hepatic impairment, the maximum daily oral dose is typically limited to 100 mg. The treatment for any condition should utilize the lowest effective dose for the shortest necessary duration.

Research Evidence / Overview of Studies for Romal

Romal, which contains the active ingredient Ketoprofen, was studied to understand its relationship to various painful and inflammatory conditions. The evidence base primarily consists of controlled clinical trials and subsequent meta-analyses, which help contextualize how patients’ symptoms were measured and observed under research conditions.

---

Evidence for Use in Chronic Joint Conditions (Rheumatoid Arthritis and Osteoarthritis)

The evidence used to contextualize Romal in chronic joint conditions is largely derived from Randomized Controlled Trials (RCTs), comparative studies, and systematic reviews involving adult populations with rheumatoid arthritis (RA) and osteoarthritis (OA). These studies were used in research exploring how symptoms change over time.

For both conditions, research primarily examined symptomatic outcomes related to physical discomfort and functional imbalance. Measured endpoints included patient-reported pain intensity, changes in functional status, and the duration of joint stiffness. The research provides context on the symptomatic measurements associated with these conditions but does not offer insight into the progression of the underlying joint disease over many years.

---

Evidence for Use in Acute Pain Management

The research base for understanding Romal in acute pain settings is characterized by short-term, single-dose, and short-course RCTs relevant in trials assessing episodic symptom patterns. This includes studies that were applied in research contexts involving fluctuating or unstable symptoms related to primary dysmenorrhea (menstrual cramps) and postoperative pain.

Research monitored outcomes related to physical discomfort, recording objective metrics like pain intensity, the need for other supplemental analgesia, and changes in physical discomfort during these acute episodes. Follow-up durations were typically limited to the immediate acute phase, meaning data for prolonged study scenarios of persistent or recurring acute pain are less available.

---

What Is Still Uncertain About Romal: Research Gaps and Limitations

Long-term data are not fully established by the core regulatory studies, as follow-up durations were limited in the pivotal trials for chronic use. The evidence is generally centered on adults, and dedicated research has not been performed on the relationship of age to the study of Romal in the pediatric population. Subgroup findings are uncertain for patients with multiple chronic conditions, as most pivotal RCTs exclude these individuals.

Key Studies & References

1. Ketoprofen (Romal) Product Monograph (Health Canada or equivalent regulatory authority)
2. WHO Model List of Essential Medicines (Relevant section on NSAIDs for pain and inflammation)

Common questions about Romal (FAQ)

Q: Is Romal the same type of medicine as [similar drug name]?

A: Romal contains the active ingredient Ketoprofen, which official sources classify as a Nonsteroidal Anti-inflammatory Drug (NSAID). This is the same broad class of medicine used for agents like ibuprofen and naproxen, sharing a primary goal of reducing inflammation and pain.

Q: Can Romal cause long-term side effects?

A: Official safety information notes that the potential risk of serious adverse reactions, specifically major cardiovascular events (like heart attack or stroke) and serious gastrointestinal events (like bleeding and ulceration), may increase with the duration of use. Official information states the risk for these serious events may increase with the duration of use.

Q: How long does Romal stay in your system after stopping it?

A: Studies on Romal's elimination show that the immediate-release form generally has a half-life of approximately 2 to 4 hours. The drug is converted by the body into an inactive form and is primarily eliminated through the kidneys.

Q: What should I know about Romal before a scheduled surgery?

A: Official documents contain important restrictions, particularly stating that Romal is contraindicated (absolutely prohibited) for managing pain immediately following coronary artery bypass graft (CABG) surgery. Official information also indicates that Romal interacts with medicines used to reduce blood clotting.

Q: What is the purpose of the different strengths Romal comes in?

A: The different strengths and formulations are designed for specific therapeutic uses. Different strengths and formulations are associated with different prescribed use scenarios, such as the management of acute pain versus chronic conditions.

Q: If Romal doesn't work for me, what does that usually mean?

A: Regulatory guidance addresses the possibility of an unsatisfactory response to treatment. If the response to treatment is initially unsatisfactory, official information suggests that adjustment of the prescribed amount may be considered, while remaining within the defined maximum limits.

Q: How quickly does Romal start working?

A: After taking the immediate-release oral form while fasting, studies show that the medication reaches its peak concentration in the bloodstream within approximately 0.5 to 2 hours. This period aligns with when the drug reaches its peak concentration in the bloodstream.

Q: Does Romal need to be taken every day?

A: Use is defined by the specific prescribed schedule; some regimens require daily administration for chronic conditions, while others are prescribed for use only as needed for acute symptoms.

Q: What is the difference between Romal and a placebo?

A: Clinical trial data provides the basis for understanding the difference. Clinical trials indicate that Romal provided a superior reduction in pain symptoms when compared to a placebo (an inactive substance).

Q: How often do the listed side effects actually occur?

A: Side effects are classified by regulatory documents according to their frequency in clinical study populations, using categories that range from Very Common to Very Rare.

Q: Can Romal cause weight changes?

A: Official safety information lists both weight gain and weight loss as adverse reactions that have been reported with Romal use. Patients are also advised to be alert for unexplained weight gain, as this may be a sign of fluid retention or congestive heart failure.

Q: How long before an expected event should Romal be taken?

A: The drug reaches maximum concentration in the blood within approximately 0.5 to 2 hours after taking the immediate-release form. This time frame indicates the period when the body achieves its maximum systemic exposure to the medicine.

Q: Can Romal be used by people with a history of liver issues?

A: Regulatory documents state that Romal is contraindicated in patients with severe hepatic insufficiency (severe liver failure). For patients with documented impaired liver function, official information requires that a lower maximum daily amount may be necessary, and conditional use is defined.

Q: Is Romal safe to use for teenagers?

A: According to official documentation, the safety and effectiveness of Romal have not been formally established in the pediatric population, which includes children and adolescents (teenagers). The lack of established data means use in this age group is not defined.

Q: Can Romal affect fertility?

A: Official warnings state that, consistent with the profile of other NSAIDs, Romal is not recommended for women who are actively trying to conceive. Its use may temporarily impair female fertility.

Q: What should I do if a side effect seems mild?

A: Official guidance indicates that patients are expected to monitor side effects they experience. Regulatory information advises patients to contact their healthcare provider if any side effects continue or become bothersome.

Q: Are there restrictions on driving or operating machinery while on Romal?

A: Yes, official product information includes warnings that Romal may cause side effects like dizziness or drowsiness. For this reason, patients are advised to avoid driving a car or operating machinery until they are certain the medication does not affect their ability to perform these activities.

How to Store and Dispose of Romal?

The storage and disposal requirements for Romal (Ketoprofen) are officially established to preserve product quality and ensure safety.

---

Storage Requirements

Romal oral forms must be stored at a controlled room temperature, typically below 25°C (77°F), to maintain its chemical integrity. The medication must be protected from both light and moisture; therefore, regulatory documents mandate keeping the product in its original container and ensuring the container remains tightly closed.

Storage Classification	Requirement
Temperature Maximum	Store below 25°C
Environmental Protection	Protect from light and moisture
Container Rule	Keep in original, tightly closed package

Disposal and Safety

It is a mandatory requirement that all forms of Romal be kept out of the sight and reach of children.

To dispose of unused or expired medicine responsibly, official guidance instructs that Romal must not be thrown away via wastewater or household waste. The preferred method is to return the unused product to a pharmacist or designated medicine take-back location, following local regulatory requirements.